Stay updated on AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial
Sign up to get notified when there's something new on the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page.

Latest updates to the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page
- Check2 days agoChange DetectedAdded a Locations section listing study sites (California, Illinois, Maryland) and updated the page to revision v3.3.3. The HHS Vulnerability Disclosure link was removed.SummaryDifference0.4%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedThe page revision indicator was updated from v3.3.1 to v3.3.2.SummaryDifference0.0%

- Check31 days agoChange DetectedThe page shows a minor version revision from v3.2.0 to v3.3.1, with no changes to study content, eligibility criteria, or listed locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check38 days agoChange DetectedRemoved the government funding lapse notice; no core study content or eligibility information was changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check52 days agoChange DetectedMinimal changes detected: only minor layout/UI updates with no impact on core study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check81 days agoChange DetectedMajor update: new operating-status notice and v3.2.0 release replaces v3.1.0; core content about status and transaction processing updated.SummaryDifference3%

Stay in the know with updates to AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page.